Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Glioblastoma Multiforme and Genetic Mutations: The Issue Is Not Over Yet. An Overview of the Current Literature.

Montemurro N.

J Neurol Surg A Cent Eur Neurosurg. 2019 Sep 24. doi: 10.1055/s-0039-1688911. [Epub ahead of print]

PMID:
31550738
2.

Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?

Tanaka S, Akimoto J, Narita Y, Oka H, Tashiro T.

J Neurosurg. 2014 Oct;121(4):818-26. doi: 10.3171/2014.6.JNS132535. Epub 2014 Aug 8.

PMID:
25105699
3.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
4.

Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.

Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.

J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16.

PMID:
25594327
5.

Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.

Zarnett OJ, Sahgal A, Gosio J, Perry J, Berger MS, Chang S, Das S.

JAMA Neurol. 2015 May;72(5):589-96. doi: 10.1001/jamaneurol.2014.3739. Review.

PMID:
25822375
6.

Therapy and progression--induced O6-methylguanine-DNA methyltransferase and mismatch repair alterations in recurrent glioblastoma multiforme.

Agarwal S, Suri V, Sharma MC, Sarkar C.

Indian J Cancer. 2015 Oct-Dec;52(4):568-73. doi: 10.4103/0019-509X.178403. Review.

7.

A systematic review of overall survival in pediatric primary glioblastoma multiforme of the spinal cord.

Konar SK, Bir SC, Maiti TK, Nanda A.

J Neurosurg Pediatr. 2017 Feb;19(2):239-248. doi: 10.3171/2016.8.PEDS1631. Epub 2016 Nov 4. Review.

PMID:
27813458
8.

Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.

Kawasoe T, Takeshima H, Yamashita S, Mizuguchi S, Fukushima T, Yokogami K, Yamasaki K.

J Neurosurg. 2015 Feb;122(2):317-23. doi: 10.3171/2014.10.JNS132159. Epub 2014 Nov 21.

PMID:
25415071
9.

Glioblastoma: pathology, molecular mechanisms and markers.

Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A.

Acta Neuropathol. 2015 Jun;129(6):829-48. doi: 10.1007/s00401-015-1432-1. Epub 2015 May 6. Review.

PMID:
25943888
10.

O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.

Jha P, Suri V, Jain A, Sharma MC, Pathak P, Jha P, Srivastava A, Suri A, Gupta D, Chosdol K, Chattopadhyay P, Sarkar C.

Neurosurgery. 2010 Dec;67(6):1681-91. doi: 10.1227/NEU.0b013e3181f743f5. Review.

PMID:
21107199
11.

Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.

Zhang G, Huang S, Zhang J, Wu Z, Lin S, Wang Y.

J Neurooncol. 2016 Apr;127(2):355-62. doi: 10.1007/s11060-015-2046-0. Epub 2016 Jan 2.

PMID:
26725096
12.

Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.

Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H.

Neurosurg Focus. 2015 Mar;38(3):E2. doi: 10.3171/2015.1.FOCUS14745. Review.

PMID:
25727224
13.
14.

Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.

Gao WZ, Guo LM, Xu TQ, Yin YH, Jia F.

J Transl Med. 2018 Dec 20;16(1):368. doi: 10.1186/s12967-018-1744-8.

15.

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme.

Greer L, Pannullo SC, Smith AW, Taube S, Yondorf MZ, Parashar B, Trichter S, Nedialkova L, Sabbas A, Christos P, Wernicke AG.

Cureus. 2017 Jun 24;9(6):e1388. doi: 10.7759/cureus.1388.

16.

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.

PMID:
22287028
17.

Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.

Ayoub Z, Geara F, Najjar M, Comair Y, Khoueiry-Zgheib N, Khoueiry P, Mahfouz R, Boulos FI, Kamar FG, Andraos T, Saadeh F, Kreidieh F, Abboud M, Skaf G, Assi HI.

Clin Neurol Neurosurg. 2019 Jul;182:92-97. doi: 10.1016/j.clineuro.2019.04.008. Epub 2019 Apr 29.

PMID:
31108342
18.

The role of metabolic therapy in treating glioblastoma multiforme.

Maroon JC, Seyfried TN, Donohue JP, Bost J.

Surg Neurol Int. 2015 Apr 16;6:61. doi: 10.4103/2152-7806.155259. eCollection 2015.

19.

Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.

Schwartz C, Romagna A, Machegger L, Weiss L, Huemer F, Fastner G, Kleindienst W, Weis S, Greil R, Winkler PA.

World Neurosurg. 2018 Dec;120:442-447. doi: 10.1016/j.wneu.2018.09.082. Epub 2018 Sep 22.

PMID:
30253992
20.

Supplemental Content

Support Center